Efficacy, safety and pharmacokinetics of apatinib plus etoposide versus apatinib alone for platinum-resistant recurrent ovarian cancer: protocol of a multicenter, open-label, randomized phase 2 trial

BACKGROUND: Currently preferred single-agent nonplatinum chemotherapy or its combination with bevacizumab results in a low response rate and modest survival benefit for platinum-resistant recurrent ovarian cancer, and thus more effective regimens are needed. In our previous phase 2 trial, apatinib p...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, Zhiguo, Lan, Chunyan, Huang, Xin, Salcedo-Hernández, Rosa A., EL-Tawab, Sally
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643946/
https://www.ncbi.nlm.nih.gov/pubmed/37969395
http://dx.doi.org/10.21037/tcr-23-1924

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643946/
https://www.ncbi.nlm.nih.gov/pubmed/37969395
http://dx.doi.org/10.21037/tcr-23-1924

Ejemplares similares